Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine + Docetaxel in mCRPC
NCT06480110Phase 2Recruiting
- Sponsor
- Rigshospitalet
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Rigshospitalet. Started Jun 2024; status: recruiting.
02
Drugs
eribulin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06480110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480110.